Expression of miR-451a in Prostate Cancer and Its Effect on Prognosis
Background: To investigate the expression of miR-451a in prostate cancer tissues and its effect on prognosis.
Methods: Each of 78 specimens of prostate cancer tissues and corresponding adjacent normal tissues were collected from patients in Changshu Hospital Affiliated to Soochow University, Changshu, China from Apr 2014 to Jun 2015. Real-time quantitative RT-PCR (qRT-PCR) was used to detect the expression of miR-451a in tissues. The relationship between the expression of miR-451a and clinical pathological parameters was analyzed. The median expression of miR-451a in the experimental group was used to distinguish the high and low expressions of miR-451a in the experimental group. Kaplan-Meier was used to analyze the survival of miR-451a high and low expression groups.
Results: The expressions of miR-451a in the patient's tissues and serum were decreased, and the correlation analysis found that they were positively correlated. ROC curve analysis showed that miR-451a had a high clinical value in the diagnosis of prostate cancer and the area under the curve was 0.921. The incidence of stage III+IV lymph node metastasis, Gleason score of >7 points and a serum Prostate-specific antigen (PSA) level of >20 ng/ml in patients of the low expression group increased significantly. The 5-yr survival rate of patients with low expression was significantly lower than that of those with high expression (P=0.005). MiR-451a was an independent factor affecting the prognosis of patients.
Conclusion: miR-451a is lowly expressed in prostate cancer, and patients with low expression have a poor prognosis.
2. Siegel RL, Miller KD, Jemal A (2017). Can-cer Statistics, 2017. CA Cancer J Clin, 67(1): 7-30.
3. Li X, Wan X, Chen H, et al (2014). Identifi-cation of miR-133b and RB1CC1 as in-dependent predictors for biochemical re-currence and potential therapeutic targets for prostate cancer. Clin Cancer Res, 20(9): 2312-2325.
4. Scher HI, Solo K, Valant J, et al (2015). Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS One, 10(10): e0139440.
5. Esfahani M, Ataei N, Panjehpour M (2015). Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev, 16(7): 2601-2611.
6. Bertoli G, Cava C, Castiglioni I (2016). Mi-croRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci, 17(3): 421.
7. Liu Z, Miao T, Feng T, et al (2015). miR-451a Inhibited Cell Proliferation and En-hanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibi-tory Factor. Biomed Res Int, 2015: 207684.
8. Minna E, Romeo P, Dugo M, et al (2016). miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thy-roid carcinoma. Oncotarget, 7(11): 12731-12747.
9. Riquelme I, Tapia O, Leal P, et al (2016). miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gas-tric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr), 39(1): 23-33.
10. Cai C, Chen QB, Han ZD, et al (2015). miR-195 Inhibits Tumor Progression by Tar-geting RPS6KB1 in Human Prostate Cancer. Clin Cancer Res, 21(21): 4922-4934.
11. Zhao Z, Stephan C, Weickmann S, et al (2017). Tissue-Based MicroRNAs as Pre-dictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies? Int J Mol Sci, 18(10): 2023.
12. Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al (2011). Investigation of miR-21, miR-141, and miR-221 in blood circula-tion of patients with prostate cancer. Tu-mour Biol, 32(3): 583-588.
13. Zhang X, Tao T, Liu C, et al (2016). Down-regulation of miR-195 promotes prostate cancer progression by targeting HMGA1. Oncol Rep, 36(1): 376-382.
14. Shen YY, Cui JY, Yuan J, et al (2018). MiR-451a suppressed cell migration and inva-sion in non-small cell lung cancer through targeting ATF2. Eur Rev Med Pharmacol Sci, 22(17): 5554-5561.
15. Shen Y, Gong JM, Zhou LL, et al (2017). MiR-451 as a new tumor marker for gas-tric cancer. Oncotarget, 8(34): 56542-56545.
16. Huang X, Yuan T, Liang M, et al (2015). Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol, 67(1): 33-41.
17. Das DK, Osborne JR, Lin HY, et al (2016). miR-1207-3p is a novel prognostic bi-omarker of prostate cancer. Transl Oncol, 9(3): 236-241.
18. Chang C, Liu J, He W, et al (2018). A regula-tory circuit HP1gamma/miR-451a/c-Myc promotes prostate cancer progression. Oncogene, 37(4): 415-426.
19. Huang JY, Zhang K, Chen DQ, et al (2015). MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic bi-omarker of hepatocelluar carcinoma. On-cotarget, 6(21): 18613-18630.
20. Sekhon K, Bucay N, Majid S, et al (2016). MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget, 7(41): 67597-67611.
21. Valberg M, Stensrud MJ, Aalen OO (2018). The surprising implications of familial as-sociation in disease risk. BMC Public Health, 18(1): 135.
22. Frank C, Fallah M, Ji J, et al (2014). The population impact of familial cancer, a major cause of cancer. Int J Cancer, 134(8): 1899-1906.
23. Kalogirou C, Spahn M, Krebs M, et al (2013). MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci, 14(11): 21414-21434.
24. Chang AJ, Autio KA, Roach M 3rd, et al (2014). High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol, 11(6): 308-323.
|Issue||Vol 50 No 4 (2021)|
|Prostate cancer Expression level Clinical pathology Prognosis|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|